ESBL colonization and acquisition in a hospital population: The molecular epidemiology and transmission of resistance genes

PLoS One. 2019 Jan 14;14(1):e0208505. doi: 10.1371/journal.pone.0208505. eCollection 2019.

Abstract

A prospective cohort study (German Clinical Trial Registry, No. 00005273) was performed to determine pre-admission colonization rates, hospital acquisition risk factors, subsequent infection rates and colonization persistence including the respective molecular epidemiology and transmission rates of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (EPE). A total of 342 EPEs were isolated from rectal swabs of 1,334 patients on admission, at discharge and 6 months after hospitalization. Inclusion criteria were patients' age > 18 years, expected length of stays > 48 hours, external referral. The EPEs were characterized by routine microbiological methods, a DNA microarray and ERIC-PCR. EPE colonization was found in 12.7 % of admitted patients, with the highest rate (23.8 %) in patients from nursing homes. During hospitalization, 8.1 % of the patients were de novo EPE colonized, and invasive procedures, antibiotic and antacid therapies were independent risk factors. Only 1/169 patients colonized on admission developed a hospital-acquired EPE infection. Escherichia coli was the predominant EPE (88.9 %), and 92.1% of the ESBL phenotypes could be related to CTX-M variants with CTX-M-1/15 group being most frequent (88.9%). A corresponding β-lactamase could not be identified in five isolates. Hospital-acquired EPE infections in patients colonized before or during hospitalization were rare. The diversity of the EPE strains was much higher than that of the underlying plasmids. In seven patients, transmission of the respective plasmid across different species could be observed indicating that the current strain-based surveillance approaches may underestimate the risk of inter-species transmission of resistance genes.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colony Count, Microbial
  • Drug Resistance, Bacterial / genetics*
  • Enterobacteriaceae / genetics
  • Enterobacteriaceae / growth & development
  • Enterobacteriaceae / isolation & purification
  • Enterobacteriaceae Infections / epidemiology
  • Enterobacteriaceae Infections / genetics
  • Enterobacteriaceae Infections / microbiology
  • Follow-Up Studies
  • Genes, Bacterial*
  • Hospitals*
  • Humans
  • Molecular Epidemiology
  • Patient Admission
  • Patient Discharge
  • Plasmids / genetics
  • Risk Factors
  • beta-Lactamases / biosynthesis*
  • beta-Lactamases / genetics

Substances

  • beta-Lactamases

Grants and funding

This work was supported by grants from the German Ministry of Education and Research (BMBF), grant numbers 01KI1204, 01KI1501, 13GW0096B and 13GW0096D. Abbott (Alere Technologies GmbH) provided support in the form of salaries for authors DW and RE, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.